Top Page
Phio Pharmaceuticals
(NASDAQ:PHIO)
Phio Pharmaceuticals (PHIO) vs. SPDR S&P 500 ETF (SPY)
Phio Pharmaceuticals Business Overview & Revenue Model
Phio Pharmaceuticals Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.08M | -3.64M | -6.33M | -7.01M | -8.89M | -3.72M |
| EBITDA | -8.09M | -7.38M | -10.64M | -11.39M | -13.44M | -8.72M |
| Net Income | -7.95M | -7.15M | -10.83M | -11.48M | -13.29M | -8.79M |
Balance Sheet | ||||||
| Total Assets | 11.51M | 5.74M | 9.36M | 12.81M | 25.17M | 15.74M |
| Cash, Cash Equivalents and Short-Term Investments | 10.71M | 5.38M | 8.49M | 11.78M | 24.06M | 14.24M |
| Total Debt | 0.00 | 0.00 | 35.00K | 170.00K | 295.00K | 642.00K |
| Total Liabilities | 1.67M | 1.01M | 1.63M | 1.97M | 3.24M | 2.72M |
| Stockholders Equity | 9.84M | 4.72M | 7.73M | 10.84M | 21.93M | 13.02M |
Cash Flow | ||||||
| Free Cash Flow | -7.28M | -7.11M | -10.75M | -12.25M | -11.91M | -8.82M |
| Operating Cash Flow | -7.27M | -7.11M | -10.75M | -12.13M | -11.86M | -8.80M |
| Investing Cash Flow | -4.00K | 8.00K | -5.00K | -121.00K | -51.00K | -19.00K |
| Financing Cash Flow | 12.59M | 4.00M | 7.41M | -26.00K | 21.72M | 16.13M |
Phio Pharmaceuticals Technical Analysis
Phio Pharmaceuticals Risk Analysis
Phio Pharmaceuticals Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $80.49M | -2.44 | -70.22% | ― | 185.71% | 79.03% | |
46 Neutral | $12.49M | -0.51 | -107.58% | ― | ― | 83.95% | |
44 Neutral | $2.44M | -0.18 | -207.73% | ― | 1.70% | -111.67% | |
43 Neutral | $8.20M | -1.81 | ― | ― | -29.78% | 88.96% | |
39 Underperform | $396.08K | >-0.01 | ― | ― | ― | 99.09% |
Phio Pharmaceuticals Corporate Events
On January 20, 2026, Phio Pharmaceuticals reported pathology and safety data from all five cohorts in its Phase 1b intratumoral PH-762 dose-escalation trial in cutaneous carcinomas, showing favorable safety and tolerability across a 20-fold dose range with no dose-limiting toxicities or clinically relevant treatment-emergent adverse effects. Among 20 patients with cSCC, 14 were pathologic responders, including 10 with complete responses (100% clearance), two with major responses (over 90% clearance) and two with partial responses (over 50% clearance), contributing to a 70% overall response rate for squamous cell carcinomas, while one patient with metastatic Merkel cell carcinoma achieved a partial response and no patients experienced disease progression, positioning PH-762 as a promising non-surgical candidate in skin cancer treatment and informing the design of follow-on clinical trials.
The most recent analyst rating on (PHIO) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Phio Pharmaceuticals stock, see the PHIO Stock Forecast page.
On December 23, 2025, Phio Pharmaceuticals announced that the U.S. Food and Drug Administration had accepted the nonclinical protocol study design for PH-762, allowing the company to begin an FDA-required toxicology study in the first quarter of 2026 ahead of a potential pivotal human trial. The company is simultaneously working to secure commercially viable PH-762 drug product that meets current Good Manufacturing Practices in 2026, funded in part by recent financing, and reported encouraging interim data from its ongoing Phase 1b dose-escalation trial in skin cancer patients, with multiple complete and partial responses, no clinical disease progression, and no dose-limiting toxicities observed to date, underscoring both the clinical potential of PH-762 and a meaningful de-risking step in its development pathway.
The most recent analyst rating on (PHIO) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Phio Pharmaceuticals stock, see the PHIO Stock Forecast page.
On November 25, 2025, Phio Pharmaceuticals announced the completion of patient enrollment in its Phase 1b clinical trial for PH-762, a siRNA compound targeting skin cancer. The trial, which evaluates safety and tolerability, showed promising results with several patients achieving complete or partial responses, and no dose-limiting toxicities observed. This milestone advances PH-762 as a potential treatment for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma, with pathology results expected in Q1 2026.
The most recent analyst rating on (PHIO) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Phio Pharmaceuticals stock, see the PHIO Stock Forecast page.
On November 3, 2025, Phio Pharmaceuticals announced agreements to exercise existing warrants for approximately 5.66 million shares of common stock, originally issued in 2024 and 2025, with exercise prices between $2.00 and $5.45 per share. The exercise of these warrants, expected to generate gross proceeds of about $13.4 million, will occur in multiple tranches, with initial closings on November 4 and 6, 2025, and additional closings by November 18, 2025. The proceeds will be used primarily for working capital and accelerating development activities for PH-762, a potential non-surgical treatment for skin cancers. H.C. Wainwright & Co. is serving as the exclusive placement agent for the offering.
The most recent analyst rating on (PHIO) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Phio Pharmaceuticals stock, see the PHIO Stock Forecast page.
On November 3, 2025, Phio Pharmaceuticals announced positive results from its Phase 1b trial of INTASYL PH-762 for cutaneous squamous cell carcinoma, with one patient achieving 100% tumor clearance, another over 90%, and a third over 50% at Day 36. The Safety Monitoring Committee reviewed the safety data favorably, noting no dose-limiting toxicities or adverse effects, underscoring the potential of PH-762 as a non-surgical treatment option, which could enhance Phio’s position in the oncology therapeutics market.
The most recent analyst rating on (PHIO) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Phio Pharmaceuticals stock, see the PHIO Stock Forecast page.
On October 31, 2025, Robert Ferrara resigned from Phio Pharmaceuticals‘ Board of Directors, including his roles on the Compensation and Audit Committees, and as Lead Independent Director. His resignation led to the Board reducing its size from six to five members. Concurrently, Phio Pharmaceuticals announced the appointment of David Deming as the new Lead Independent Director. Deming, who joined the Board in February 2025, brings over 30 years of experience in investment banking and asset management, which is expected to be a valuable resource as the company advances its gene silencing technology aimed at eliminating cancer.
The most recent analyst rating on (PHIO) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Phio Pharmaceuticals stock, see the PHIO Stock Forecast page.